## STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation	Location in study
Title and abstract	1	(a) Indicate the study's design with a commonly used term in	Page 1
		the title or the abstract	
		(b) Provide in the abstract an informative and balanced	Page 4
		summary of what was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the	Page 6
-		investigation being reported	
Objectives	3	State specific objectives, including any prespecified	Page 6
		hypotheses	
Methods			
Study design	4	Present key elements of study design early in the paper	Pages 7-8
Setting	5	Describe the setting, locations, and relevant dates, including	Page 7
		periods of recruitment, exposure, follow-up, and data	
		collection	
Participants	6	(a) Give the eligibility criteria, and the sources and methods of	N/A
		selection of participants. Describe methods of follow-up	
		(b) For matched studies, give matching criteria and number of	N/A
		exposed and unexposed	
Variables	7	Clearly define all outcomes, exposures, predictors, potential	Pages 7-9
		confounders, and effect modifiers. Give diagnostic criteria, if	
		applicable	
Data sources/	8*	For each variable of interest, give sources of data and details	Pages 7-8
measurement		of methods of assessment (measurement). Describe	
		comparability of assessment methods if there is more than one	
D'		group	37/4
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A
Quantitative variables	11	Explain how quantitative variables were handled in the	N/A
		analyses. If applicable, describe which groupings were chosen and why	
Statistical methods	12	(a) Describe all statistical methods, including those used to	N/A
	12	control for confounding	IV/A
		(b) Describe any methods used to examine subgroups and	N/A
		interactions	1771
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, explain how loss to follow-up was addressed	N/A
		(g) Describe any sensitivity analyses	N/A
Results		<u>,</u> ,	
Participants	13*	(a) Report numbers of individuals at each stage of study—eg	Pages 10-11
	13	numbers potentially eligible, examined for eligibility,	1 4500 10 11
		confirmed eligible, included in the study, completing follow-	
		up, and analysed	
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	Pages 10-11
•			_

		clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	N/A
		(c) Summarise follow-up time (eg, average and total amount)	Pages 10-11
Outcome data	15*	Report numbers of outcome events or summary measures over time	Pages 10-11
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder- adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Pages 10-11
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	Page 12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Pages 13-14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Pages 12-14
Generalisability	21	Discuss the generalisability (external validity) of the study results	Pages 14-15
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 2

<sup>\*</sup>Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.